Cargando…

Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses

BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Tao, Li, Keyu, Niu, Nan, Shao, Yingkuan, Ding, Ding, Thomas, Dwayne L., Jing, Hao, Fujiwara, Kenji, Hu, Haijie, Osipov, Arsen, Yuan, Chunhui, Wolfgang, Christopher L., Thompson, Elizabeth D., Anders, Robert A., He, Jin, Mou, Yiping, Murphy, Adrian G., Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/
https://www.ncbi.nlm.nih.gov/pubmed/35346322
http://dx.doi.org/10.1186/s13045-022-01253-z
Descripción
Sumario:BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data. RESULTS: This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B(+)CD8(+) effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1(−)EOMES(−)CD8(+) effector T cells are associated with long-term survival. However, only the density of PD-1(−)EOMES(−)CD8(+) T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1(+) tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1(+) M1 or M2, PD-L1(−) M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1(−) M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1(+) tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion. CONCLUSIONS: This study suggests that the densities of Granzyme-B(+)CD8(+) effector T cells and non-exhausted PD-1(−)EOMES(−)CD8(+) T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1(+) tumor-associated macrophages as the immunotherapy for cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01253-z.